[go: up one dir, main page]

BR112016009465A2 - Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso - Google Patents

Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso

Info

Publication number
BR112016009465A2
BR112016009465A2 BR112016009465A BR112016009465A BR112016009465A2 BR 112016009465 A2 BR112016009465 A2 BR 112016009465A2 BR 112016009465 A BR112016009465 A BR 112016009465A BR 112016009465 A BR112016009465 A BR 112016009465A BR 112016009465 A2 BR112016009465 A2 BR 112016009465A2
Authority
BR
Brazil
Prior art keywords
ohsv
herpes simplex
simplex virus
recombinant oncolytic
oncolytic herpes
Prior art date
Application number
BR112016009465A
Other languages
English (en)
Other versions
BR112016009465A8 (pt
Inventor
Uchida Hiroaki
COHEN Justus
C Glorioso Joseph Iii
Grandi Paola
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of BR112016009465A2 publication Critical patent/BR112016009465A2/pt
Publication of BR112016009465A8 publication Critical patent/BR112016009465A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

VÍRUS HERPES SIMPLEX ONCOLÍTICO RECOMBINANTE (OHSV), ÁCIDO NUCLEICO O CODIFICANDO, ESTOQUE VIRAL E COMPOSIÇÃO O COMPREENDENDO, BEM COMO SEU USO. A presente invenção proporciona um Vírus Herpes Simplex oncolítico recombinante (oHSV) que compreende um ligante não-HSV específico para uma molécula (proteínas, lipídios, ou determinante de hidrato de carbono) presente na superfície de uma célula (como uma célula cancerosa) e um ou mais cópias de uma ou mais sequências alvo microRNA inserido em um ou mais loci de genes de HSV, de preferência, um ou mais genes de HSV (s) necessárias para a replicação do HSV em células normais (isto é, não cancerosas). A invenção proporciona ainda existências e composições farmacêuticas que compreendem o inventivo oHSV e métodos para matar células de tumor, empregando a oHSV inventivo.
BR112016009465A 2013-10-28 2014-10-28 vetor de hsv oncolítico. BR112016009465A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896497P 2013-10-28 2013-10-28
PCT/US2014/062676 WO2015066042A1 (en) 2013-10-28 2014-10-28 Oncolytic hsv vector

Publications (2)

Publication Number Publication Date
BR112016009465A2 true BR112016009465A2 (pt) 2017-10-03
BR112016009465A8 BR112016009465A8 (pt) 2018-01-30

Family

ID=53005031

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009465A BR112016009465A8 (pt) 2013-10-28 2014-10-28 vetor de hsv oncolítico.

Country Status (17)

Country Link
US (5) US10201575B2 (pt)
EP (3) EP3063279B1 (pt)
JP (3) JP6588024B2 (pt)
KR (2) KR102490462B1 (pt)
CN (2) CN113717952A (pt)
AU (1) AU2014342465B2 (pt)
BR (1) BR112016009465A8 (pt)
CA (1) CA2928956A1 (pt)
DK (1) DK3184641T3 (pt)
ES (2) ES2781852T3 (pt)
IL (2) IL245312B (pt)
MX (2) MX379501B (pt)
NZ (1) NZ720021A (pt)
PT (1) PT3184641T (pt)
RU (1) RU2719190C2 (pt)
SG (1) SG11201603119RA (pt)
WO (1) WO2015066042A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
EP3063279B1 (en) 2013-10-28 2020-01-01 University of Pittsburgh - Of the Commonwealth System of Higher Education Oncolytic hsv vector
HUE054563T2 (hu) * 2015-02-11 2021-09-28 Univ Bologna Alma Mater Studiorum Újracélzott herpeszvírus glikoprotein-H fúzióval
DK3400293T4 (da) 2016-01-08 2023-08-28 Replimune Ltd Modificeret onkolytisk virus
DK3408382T3 (da) 2016-01-27 2022-06-20 Oncorus Inc Onkolytiske virale vektorer og anvendelser deraf
KR102457098B1 (ko) * 2016-03-19 2022-10-21 엑수마 바이오테크, 코포레이션 림프구를 형질도입시키기 위한 방법 및 조성물, 및 이의 조절된 확장
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
DK3377637T3 (da) * 2016-04-08 2020-05-18 Krystal Biotech Inc Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
NZ746916A (en) * 2016-04-22 2020-08-28 Immvira Co Ltd Construction of oncolytic herpes simplex viruses (ohsv) obligate vector and constructs for cancer therapy
US20190106709A1 (en) * 2016-04-29 2019-04-11 Virogin Biotech Canada Ltd Hsv vectors with enhanced replication in cancer cells
EP3469070B1 (en) 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus with modified glycoprotein b
WO2017211944A1 (en) * 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein d
NZ749586A (en) * 2016-06-14 2023-06-30 Univ Pittsburgh Commonwealth Sys Higher Education Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
MX2019000252A (es) 2016-06-30 2019-10-09 Oncorus Inc Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
CN109563507B (zh) * 2016-07-08 2024-03-05 埃克苏马生物技术公司 用于转导淋巴细胞及调节其活性的方法及组合物
KR102780496B1 (ko) * 2016-07-29 2025-03-11 오하이오 스테이트 이노베이션 파운데이션 종양용해성 바이러스에 의한 PTEN-Long의 발현
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CA3052463A1 (en) * 2017-02-03 2018-08-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
WO2018161825A1 (zh) * 2017-03-09 2018-09-13 厦门大学 一种重组单纯疱疹病毒及其用途
EP3658165A4 (en) 2017-07-26 2021-09-01 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND THEIR USES
EP3833765A1 (en) * 2017-08-09 2021-06-16 The Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
CN111712250A (zh) * 2017-11-16 2020-09-25 复诺健生物科技加拿大有限公司 靶向部分修饰的溶瘤病毒
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US20200376142A1 (en) * 2018-02-19 2020-12-03 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
MA52542A (fr) 2018-04-13 2021-02-24 Bluebird Bio Inc Thérapie cellulaire adoptive
US10786438B2 (en) 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
CA3101993A1 (en) * 2018-05-31 2019-12-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Antigenically stealthed oncolytic viruses
KR101998793B1 (ko) * 2018-09-04 2019-07-10 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CA3142935A1 (en) * 2019-06-10 2020-12-17 Infectious Disease Research Institute Methods and compositions of astrovirus replicons
KR20220078650A (ko) 2019-10-10 2022-06-10 온코루스, 인크. 이중 바이러스 및 이중 종양용해 바이러스 및 치료 방법
US20240150787A1 (en) * 2019-11-01 2024-05-09 University Of Houston System Oncolytic virotherapy with induced anti-tumor immunity
WO2021246815A1 (ko) * 2020-06-03 2021-12-09 주식회사 젠셀메드 Hvec의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
AU2021287536B2 (en) 2020-06-12 2024-12-05 Gencellmed Inc. Multi-targeting recombinant herpes simplex viruses and use thereof
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
CN117412986A (zh) 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
WO2023147566A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
WO2024151990A1 (en) * 2023-01-13 2024-07-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Effective oncolytic herpes simplex virus vector retargeting
WO2024182737A1 (en) * 2023-03-01 2024-09-06 The Brigham And Women’S Hospital, Inc. Oncolytic viruses to treat brain cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
JP4255211B2 (ja) 1997-12-17 2009-04-15 イミュネックス・コーポレーション ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
WO2002076216A1 (en) * 2001-03-27 2002-10-03 Medigene, Inc. Viral vectors and their use in therapeutic methods
PL373594A1 (en) 2001-10-04 2005-09-05 Immunex Corporation Ul16 binding protein 4
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
WO2003073918A2 (en) 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP2377882A1 (en) 2004-10-28 2011-10-19 University of Pittsburgh of the Commonwealth System of Higher Education Peripherally delivered glutamatic acid decarboxylase gene therapy for spinal cord injury pain
EP3002330A1 (en) 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
CA2687301C (en) 2007-05-09 2016-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
WO2009144755A1 (en) * 2008-05-29 2009-12-03 Alma Mater Studiorum - Universita' Di Bologna Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
WO2010105277A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
JP5652830B2 (ja) 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
WO2011130749A2 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
RU2020105656A (ru) 2013-07-17 2021-01-27 Юниверсити Оф Питтсбург- Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Нетоксичные векторы на основе впг для применений в эффективной доставке генов и комплементирующие клетки для их продуцирования
EP3063279B1 (en) * 2013-10-28 2020-01-01 University of Pittsburgh - Of the Commonwealth System of Higher Education Oncolytic hsv vector

Also Published As

Publication number Publication date
JP2016537020A (ja) 2016-12-01
BR112016009465A8 (pt) 2018-01-30
ES2810800T3 (es) 2021-03-09
HK1225756A1 (en) 2017-09-15
JP2020058341A (ja) 2020-04-16
EP3063279A1 (en) 2016-09-07
PT3184641T (pt) 2020-08-21
IL272480A (en) 2020-03-31
US10188686B2 (en) 2019-01-29
KR20210145296A (ko) 2021-12-01
RU2016120618A (ru) 2017-12-06
JP6919912B2 (ja) 2021-08-18
US20190262410A1 (en) 2019-08-29
US11883448B2 (en) 2024-01-30
EP3778906A1 (en) 2021-02-17
CN106068326A (zh) 2016-11-02
IL272480B (en) 2021-06-30
US10201575B2 (en) 2019-02-12
CN113717952A (zh) 2021-11-30
AU2014342465B2 (en) 2018-03-08
CA2928956A1 (en) 2015-05-07
RU2719190C2 (ru) 2020-04-17
MX2021001158A (es) 2021-04-28
EP3184641A1 (en) 2017-06-28
KR102330183B1 (ko) 2021-11-23
JP2021180661A (ja) 2021-11-25
MX379501B (es) 2025-03-11
AU2014342465A1 (en) 2016-06-02
EP3063279B1 (en) 2020-01-01
KR20160108301A (ko) 2016-09-19
US20160250267A1 (en) 2016-09-01
EP3778906B1 (en) 2025-07-02
US20170035819A1 (en) 2017-02-09
DK3184641T3 (da) 2020-08-03
US10172893B2 (en) 2019-01-08
EP3184641B1 (en) 2020-07-08
WO2015066042A1 (en) 2015-05-07
NZ720021A (en) 2022-08-26
SG11201603119RA (en) 2016-05-30
ES2781852T3 (es) 2020-09-08
US20210138007A1 (en) 2021-05-13
JP7262134B2 (ja) 2023-04-21
RU2016120618A3 (pt) 2018-05-22
MX2016005488A (es) 2016-10-03
IL245312B (en) 2020-02-27
JP6588024B2 (ja) 2019-10-09
US10576115B2 (en) 2020-03-03
IL245312A0 (en) 2016-06-30
EP3063279A4 (en) 2017-05-17
CN106068326B (zh) 2021-06-18
KR102490462B1 (ko) 2023-01-19
US20170274025A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
BR112016009465A2 (pt) Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso
BR112018075479A2 (pt) portadores híbridos para carga de ácido nucleico
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
CO2018004763A2 (es) Edición genómica multiplexada
CY1121591T1 (el) Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου
MX390848B (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
BR112019001887A2 (pt) composições e métodos para o tratamento de doença associada a cep290
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
BR112017014917A2 (pt) elementos regulatórios pós-transcricionais modificados de hepatite
BR112014031891A2 (pt) direcionamento genético nas plantas utilizando vírus de dna
BR112015000710A8 (pt) Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
BR112017028205A2 (pt) molécula de rna, vetor, célula hospedeira, composição farmacêutica, kit, e, uso de uma ou mais utrs.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
BR112015022491A2 (pt) variantes de inibidor de tecido de metaloprotease tipo três (timp-3), ácido nucleico isolado, vetor de expressão, célula hospedeira isolada e método para produzir uma muteína de timp-3 recombinante, bem como composição e seu uso
WO2018104909A3 (en) Dna methylation profiling for t-cell immunotherapy
PH12015502096A1 (en) Thymidine kinase diagnostic assay for gene therapy applications
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
BR112018074472A2 (pt) interfaces proteicas
CL2014003167A1 (es) Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6.
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
BR112016024458A2 (pt) antígeno e do hepadnavírus marcado e seu uso em triagem de substâncias antivirais
AR101440A1 (es) MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.